Evidence map›Paper›PMID 34642698›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA.

Rebecca Earnest, Rockib Uddin, Nicholas Matluk, Nicholas Renzette, Katherine J Siddle, Christine Loreth, Gordon Adams, Christopher H Tomkins-Tinch, Mary E Petrone, Jessica E Rothman and 35 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

45 authors.

Rebecca EarnestDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA.
Rockib UddinDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA.
Nicholas MatlukMaine Center for Disease Control and Prevention, Augusta, ME 04333.
Nicholas RenzetteThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Katherine J SiddleBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Christine LorethBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Gordon AdamsBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Christopher H Tomkins-TinchBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Mary E PetroneDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA.
Jessica E RothmanDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA.
Mallery I BrebanDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA.
Robert Tobias KochDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA.
Kendall BilligDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA.
Joseph R FauverDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA.
Chantal B F VogelsDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA.
Sarah TurbettDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA.
Kaya BilguvarYale Center for Genome Analysis, Yale University, New Haven, CT 06510, USA.
Bony De KumarYale Center for Genome Analysis, Yale University, New Haven, CT 06510, USA.
Marie L LandryDepartments of Laboratory Medicine and Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.
David R PeaperDepartments of Laboratory Medicine and Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.
Kevin KellyThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Greg OmerzaThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Heather GrieserMaine Center for Disease Control and Prevention, Augusta, ME 04333.
Sim MeakMaine Center for Disease Control and Prevention, Augusta, ME 04333.
John MarthaMaine Center for Disease Control and Prevention, Augusta, ME 04333.
Hannah H DeweyThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Susan KalesThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Daniel BerenzyThe Jackson Laboratory, Bar Harbor, ME 04609, USA.
Kristin Carpenter-AzevedoRhode Island Department of Health, State Health Laboratories, Providence, RI 02904, USA.
Ewa KingRhode Island Department of Health, State Health Laboratories, Providence, RI 02904, USA.
Richard C HuardRhode Island Department of Health, State Health Laboratories, Providence, RI 02904, USA.
Sandra C SmoleMassachusetts Department of Public Health, Boston MA 02130, USA.
Catherine M BrownMassachusetts Department of Public Health, Boston MA 02130, USA.
Timelia FinkMassachusetts Department of Public Health, Boston MA 02130, USA.
Andrew S LangMassachusetts Department of Public Health, Boston MA 02130, USA.
Glen R GallagherMassachusetts Department of Public Health, Boston MA 02130, USA.
Pardis C SabetiBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Stacey GabrielBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Bronwyn L MacInnisBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
New England Variant Investigation Team
Ryan TewheyDepartment of Medical Genetics, Acibadem University School of Medicine, Istanbul, Turkey.
Mark D AdamsThe Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Daniel J ParkBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jacob E LemieuxDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA.
Nathan D GrubaughDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NRSA Training CoreTL1TR001864 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$9.9M
NCATS NIH HHS TL1 TR001864NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant quickly rose to dominance in mid-2021, displacing other variants, including Alpha. Studies using data from the United Kingdom and India estimated that Delta was 40-80% more transmissible than Alpha, allowing Delta to become the globally dominant variant. However, it was unclear if the ostensible difference in relative transmissibility was due mostly to innate properties of Delta's infectiousness or differences in the study populations. To investigate, we formed a partnership with SARS-CoV-2 genomic surveillance programs from all six New England US states. By comparing logistic growth rates, we found that Delta emerged 37-163% faster than Alpha in early 2021 (37% Massachusetts, 75% New Hampshire, 95% Maine, 98% Rhode Island, 151% Connecticut, and 163% Vermont). We next computed variant-specific effective reproductive numbers and estimated that Delta was 58-120% more transmissible than Alpha across New England (58% New Hampshire, 68% Massachusetts, 76% Connecticut, 85% Rhode Island, 98% Maine, and 120% Vermont). Finally, using RT-PCR data, we estimated that Delta infections generate on average ∼6 times more viral RNA copies per mL than Alpha infections. Overall, our evidence indicates that Delta's enhanced transmissibility could be attributed to its innate ability to increase infectiousness, but its epidemiological dynamics may vary depending on the underlying immunity and behavior of distinct populations.

Identifiers

PMID34642698
PMCPMC8509091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.